Immuron announces new DoD research award for NMRC

Immuron is pleased to announce the funding of a new research agreement for the Naval Medical Research Command, and Walter Reed Army Institute of Research Silver Spring, MD, USA. The focus of this new research agreement is to develop an enhanced formulation of Travelan potentially expanding the coverage of the product as a therapeutic measure against endemic military relevant diarrheal pathogens. This work will utilize the extensive experience of the US Department of Defense human infectious disease vaccine programs and will target key protective antigens of the major enteric bacterial pathogens Campylobacter, Shigella and Entertoxigenic E. coli strains not present in the current product formulation. Immuron will now negotiate a sub award for collaboration with NMRC and WRAIR to advance this research.